HS-110 (viagenpumatucel-L), an Off-the-Shelf Allogeneic Cell Therapy Designed to Stimulate Immune Responses Against Non-Small Cell Lung Cancer (NSCLC)
Tumors have evolved multiple mechanisms to avoid immune detection and induce tolerance that prevents the body’s own ability to combat cancer. Based on the gp96 platform, HS-110 (viagenpumatucel-L) is an allogeneic “off-the-shelf” cellular vaccine derived from a lung adenocarcinoma cancer cell line and genetically modified to secrete a wide range of cancer-associated antigens bound to the immunostimulatory chaperone gp96. This approach is designed to stimulate and facilitate uptake of these antigens by professional antigen-presenting cells (APCs), which in turn activate a broad, T-cell mediated immune response against a patient’s cancer.